Bruceine D suppressed osteoclast formation via STAT3/NF-κB/NFATc1 signaling and protected postmenopausal osteoporosis

Cyclovirobuxine Prevents Osteoclastogenesis and Estrogen Deficiency-Induced Bone Loss by Inhibiting ROS Generation via the PI3K/AKT/FOXO1 Pathway

The results suggest that CVB suppresses osteoclastogenesis and their resorptive function through modulation of MAPK and PI3K/AKT/FOXO1 pathways and by enhancing antioxidant defense, which has potential therapeutic value for antiosteoporosis treatment.

CaMKIIγ inhibition attenuates osteoclastogenesis via the NF-κB-NFATc1 axis and protects against ovariectomy-induced osteoporosis.

Osteoporosis features excessive osteoclast-mediated bone resorption, and long-term safety concerns with current antiresorptives and rebound after discontinuation underscore the need for new therapeutic targets. Calcium/calmodulin-dependent kinases (CaMKs) have been linked to osteoclastogenesis, yet which CaMKII isoform...

The marine drug plitidepsin alleviates osteoporosis in estrogen-deficient mice by suppressing ROS-mediated NRF2/HO-1 signaling and osteoclast formation

Marine-derived compounds represent an important source of innovative therapeutics owing to their structural diversity and broad bioactivity; however, their potential in osteoporosis therapy remains insufficiently explored. This study investigated the effects of plitidepsin (Pli), a marine-origin cyclic peptide, on os...

Palmitoylethanolamine alleviates osteoclast activation and reduces bone loss in osteoporosis by regulating mitochondrial function.

PEA impairs mitochondrial function in RANKL-induced BMMs, thereby repressing osteoclast differentiation via the YTHDC1/m6A-RELA/NF-κB signaling axis, which provides a novel molecular mechanism of PEA in osteoporosis treatment.

Trans-zeatin suppresses osteoclastogenesis and prevents estrogen deficiency-induced bone loss by modulating Nrf2-mediated redox homeostasis and AKT signaling.

Postmenopausal osteoporosis (PMOP) is a metabolic bone disorder driven by excessive osteoclast (OC) activity, but current therapies are limited by adverse effects. Trans-zeatin (TZ), a naturally occurring plant cytokinin with antioxidant properties, has not been investigated in bone metabolism. Here, we show that TZ su...

USP18 is downregulated in an osteoporosis model and alleviates osteoblast inflammation and apoptosis by deubiquitinating TAK1 to inhibit the MAPK pathway